Compare AbCellera Biologics Inc (ABCL) vs SpaceX (SPCX) Price & Performance

AbCellera Biologics IncTrade

SpaceXTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs SpaceX — how do they compare? AbCellera Biologics Inc trades at $9.23 (market cap $2.99B), while SpaceX trades at $135.14 (market cap $1.76T). The key difference: SpaceX is far larger — about 588.6× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals.

	ABCL	SPCX
Market Cap	$2.99B	$1.76T
Sector	Health	Technology
52-Week High	$9.76	$202.09
52-Week Low	$2.78	$108.27
Enterprise Value	$2.58B	$1.70T

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.

The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.

SpaceX

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABCL

View details →

SPCX

SpaceX shares rebound near IPO price amid ambitious $1T revenue goal by 2030, but timeline seen as aggressive.24/7 Wall Street · 4 hours agoBullish SpaceX's AI revenue soars 247% YoY, set to dominate by Q3 with $300B potential by 2027Seeking Alpha · 4 hours agoBullish Investor Ron Baron predicts SpaceX could reach a $40 trillion valuation in 15 years, echoing his successful Tesla bet.24/7 Wall Street · 5 hours agoBullish View details →

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

About SpaceX

SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.